Furthermore, given that the vast majority of AD cases (that is, late onset AD) do not carry mutations in the genes (APP, PS1, Tau) on which the amyloid transgenic mouse models have been based, it is clear that alternative animal model systems to study cognitive decline are also required to complement these amyloid transgenic studies. The gene discussed is MAPT; the disease is Alzheimer disease.